Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Sci Transl Med. 2017 Apr 12;9(385):eaak9679. doi: 10.1126/scitranslmed.aak9679.
Sci Transl Med. 2017.
PMID: 28404866
Free PMC article.